Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endostat is a recombinant human endostatin, an endogenous 20-kDa protein fragment derived from the C-terminus of collagen XVIII. It acts as a potent inhibitor of angiogenesis by interfering with the pro-angiogenic signaling of vascular endothelial growth factor (VEGF) and binding to endothelial cell surface receptors such as integrins and glypicans. This inhibition leads to reduced endothelial cell proliferation, migration, and increased apoptosis, ultimately suppressing tumor growth and metastasis by limiting the tumor's blood supply. In clinical trials, Endostat is often administered via continuous intravenous infusion, frequently in combination with immunotherapy or chemotherapy, for the treatment of various advanced solid tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on endostatin.